2 researched Pharma Biotech entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Direct Answer Healx's 2026 revenue fix pivots from generic AI-drug-discovery licensing to three locked engines: outcome-locked rare-disease-target-validation contracts at $250K–$750K/year for mid-market biotech, vertical SaaS for ultra-rare…
Read full answer ↗Direct Answer M Booth Health's revenue issues in 2026 were fixed by shifting from fragile pharma retainer dependence to a tiered outcome-linked pricing model, deploying CRM-first lead orchestration, adopting an agency partner co-delivery mo…
Read full answer ↗